WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock Ownership - Who owns Enliven Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Enliven Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Helen Louise CollinsMed2026-07-172,184$53.42
$116.67kSell
Helen Louise CollinsMed2026-07-1763$53.92
$3.40kSell
Benjamin HohlCFO2026-07-17123$53.87
$6.63kSell
Benjamin HohlCFO2026-07-172,638$53.38
$140.82kSell
Helen Louise CollinsMed2026-07-175,000$2.48
$12.40kBuy
Benjamin HohlCFO2026-07-172,564$52.32
$134.14kSell
Benjamin HohlCFO2026-07-17369$51.48
$19.00kSell
Benjamin HohlCFO2026-07-17324$49.97
$16.19kSell
Benjamin HohlCFO2026-07-171,072$2.48
$2.66kBuy
Helen Louise CollinsMed2026-07-17231$50.05
$11.56kSell

1 of 10

ELVN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ELVN insiders and whales buy or sell their stock.

ELVN Shareholders

What type of owners hold Enliven Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC14.92%9,087,504$490.27MInsider
David P. Bonita13.79%8,398,136$453.08MInsider
5am Partners VI LLC13.37%8,142,154$439.27MInsider
Orbimed Advisors LLC13.07%7,959,538$429.42MInstitution
Rishi Gupta13.06%7,951,463$428.98MInsider
Fmr LLC11.21%6,829,246$368.44MInstitution
Polar Capital Holdings PLC8.32%5,065,933$273.31MInstitution
Blackrock Inc6.05%3,684,707$198.79MInstitution
Ra Capital Management LP5.87%3,576,813$192.97MInsider
Commodore Capital LP5.38%3,275,000$176.69MInstitution

1 of 3

ELVN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ELVN51.41%48.59%Net SellingNet Selling
TLX0.76%7.56%Net Buying
ARQT77.49%22.51%Net SellingNet Selling
GPCR31.31%10.35%Net SellingNet Buying
NAMS75.24%24.76%Net SellingNet Buying
View Top Biotech Stocks

Enliven Therapeutics Stock Ownership FAQ

Who owns Enliven Therapeutics?

Enliven Therapeutics (NASDAQ: ELVN) is owned by 103.09% institutional shareholders, 97.44% Enliven Therapeutics insiders, and 0.00% retail investors. Orbimed Advisors LLC is the largest individual Enliven Therapeutics shareholder, owning 9.09M shares representing 14.92% of the company. Orbimed Advisors LLC's Enliven Therapeutics shares are currently valued at $498.09M.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.